Single tissue samples from head and neck squamous cell carcinomas are representative regarding the entire tumor's chemosensitivity to cisplatin and docetaxel

Onkologie

Volumn 32, Issue 5, 2009, Pages 264-272

  Wichmann, Gunnar ^a,c   Horn, Iris Susanne ^a   Boehm, Andreas ^a   Mozet, Christian ^a   Tschöp, Katrin ^a   Dollner, Ralph ^b   Dietz, Andreas ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Head and neck tumor; HNSCC; In vitro

Indexed keywords

CISPLATIN; COLLAGENASE; DOCETAXEL; METHANOL;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLONY FORMATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DILUTION; ENZYMATIC DEGRADATION; EPITHELIUM; EX VIVO STUDY; FEMALE; GIEMSA STAIN; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IC 50; INHIBITION KINETICS; MALE; MICROTITER PLATE ASSAY; RELIABILITY; SAMPLE; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAXOIDS; TREATMENT OUTCOME;

EID: 67549098233     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209148     Document Type: Article

References (38)

1. Adelstein DJ, Saxton JP, Lavertu P, Tuason L, Wood BG, Wanamaker JR, Eliachar I, Strome M, van Kirk MA: A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 1997;19:567-575.
2. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-1171.
3. Forastiere AA, Trotti A, Pfister DG, Grandis JR: Head and neck cancer: recent advances and new standards of care. J Clin Oncol 2006;24:2603-2605.
4. Dietz A, Nollert J, Eckel H, Volling P, Schroeder M, Staar S, Conradt C, Helmke B, Dollner R, Mueller RP, Wannenmacher M, Weidauer H, Rudat V: Organerhalt beim fortgeschrittenen Larynxund Hypopharynxkarzinom durch primäre Radiochemotherapie. HNO 2002;50:146-154.
5. Higgins KM, Wang JR: State of head and neck surgical oncology research - a review and critical appraisal of landmark studies. Head Neck 2008;30:1636-1642.
6. Scagliotti G, Purvish P, von Pavel J, Biesma B, Vansteenkiste J, Manegold C, Simms L, Posther Sugarman K, Obasaju C, Blatter J: Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Abstract PRS-3, 12th World Conference on Lung Cancer (WCLC) 2007. J Thoracic Oncology 2007;8(suppl 4):S306.
7. Sarini J, Bocciolini C, Fournier C, Penel N, Kara A, Van JT, Lefebre JL: Induction chemotherapy and larynx preservation: is such a practice useful? Bull Cancer 2002;89:411-417.
8. Dietz A, Keilholz U, Werner J, Hagen R, Flentje M, Iro H: Current role for induction chemotherapy in head and neck tumors. Laryngorhinootologie 2008;87:237-243; discussion 244.
9. Heuser M, Kopun M, Rittgen W, Granzow C: Cytotoxicity determination without photochemical artifacts. Cancer Lett 2005;223:57-66.
10. Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR: Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int 2006;6:25.
11. Rajamaran R, Rajaraman MM, Rajaraman SR, Guernsey DL: Neosis - a paradigm of self-renewal in cancer. Cell Biol Int 2005;29:1084-1097.
12. Cabelguenne A, Blons H, Waziers De I, Carnot F, Houllier A-M, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000;18:1465-1473.
13. Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR: Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 2004;26:870-877.
14. Akervall J, Guo X, Qian CN, Schoumans J, Leeser B, Kort E, Cole A, Resau J, Bradford C, Carey T, Wennerberg J, Anderson H, Tennvall J, Teh BT: Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res 2004;10:8204-8213.
15. Zhang P, Zhang Z, Zhou X, Qiu W, Chen F, Chen W: Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer 2006;6:224.
16. Stordal B, Pavlakis N, Davey R: A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev 2007;33:688-703.
17. Dollner R, Granzow C, Werner JA, Dietz A: Is there a role for chemosensitivity tests in head and neck cancer? Onkologie 2004;27:310-315.
18. Von Hoff D: He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 1990;82:96-101.
19. Hoffman RM: In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Anal 1991;5:133-143.
20. Dean M, Fijo T, Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284.
21. Dietz A, Tschöp K, Wichmann G, Granzow C: Method and kit for the ex vivo evaluation of the response of a tumor to conditions to be tested. 2008. US-Provisional Ser. No. 61/044,082.
22. Dollner R, Granzow C, Helmke BM, Ruess A, Schad A, Dietz A: The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 2004;24:325-331.
23. Granzow C, Kopun M, Kröber T: Riboflavin-mediated photosensitization of vinca alkaloids distorts drug sensitivity assays. Cancer Res 1995;55:4837-4843.
24. Granzow C, Kopun M, Heuser M, Herth F, Becker HD: Chemoresistance of human lung tumor stromal cells. Amer Assn Cancer Res 95th Ann Meet Proc suppl 2004, abstr LB-82.
25. Biorklund A, Hakansson L, Stenstan B, Trope C, Akerman M: Heterogeneity of non-Hodgkin's lymphomas as regards sensitivity to cytostatic drugs. An in vitro study. Eur J Cancer 1980;16:647-654.
26. Tanigawa N, Mizuno YHT, Hashimura T, Honda K, Satomura K, Hikasa Y, Niwa O, Sugahara T, Yoshida O, Kern DH, Morton DL: Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay. Cancer Res 1984;44:2309-2312.
27. American Joint Committee on Cancer: Comparison Guide: Cancer Staging Manual Fifth versus Sixth Edition. 2003. www.cancerstaging.org/products/ ajccguide.pdf; 3/3/2008.
28. Desoize B, Berthiot G, Manot L, Coninx P, Dumont P: Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. European J Cancer A 1996;32:1734-1738.
29. Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ: Phase I and pharmakokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993;53:523-527.
30. Gey GO, Coffman WD, Kubicek MT: Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Cancer Res 1952;12:264-265.
31. Master JRW: Human cancer cell lines: fact and fantasy. Nature Rev Mol Cell Biol 2000;1:233-236.
32. Dollner R, Kopun M, Dietz A, Wiessler M, Granzow C: Chemoreactivity profiling of HNSCC: equipotentiality of platinum compounds and glufosfamide, a novel alkylating agent. Proc Am Assn Cancer Res 2002;43:926-931.
33. Styczynski J, Drewa T: Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta Biochim Polonia 2007;4:717:726.
34. Jordan CT, Guzman ML, Noble M: Cancer stem cells. N Engl J Med 2006;355:1253-1261.
35. Freeman AE, Hoffman RM: In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 1986;83:2694-2698.
36. Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J: Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002;24:437-442.
37. Yan B, Yang X, Lee TL, Friedman J, Tang J, van Waes C, Chen Z: Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-kappaB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol 2007;8:R78.
38. Yan B, Chen G, Saigal K, Yang X, Jensen ST, van Waes C, Stoeckert CJ, Chen Z: Systems biologydefined NF-kappaB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status. Genome Biol 2008;9:R53.